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Abstract
Introduction To evaluate the incidence of central nervous
system (CNS) involvement in patients with breast cancer
treated with a taxane-based chemotherapy regimen and to
determine predictive factors for CNS relapse.
Methods The medical files of patients with early breast cancer
(n = 253) or advanced stage breast cancer (n = 239) as well of
those with other solid tumors (n = 336) treated with or without
a taxane-based chemotherapy regimen during a 42-month
period were reviewed. HER2/neu overexpression was identified
by immunohistochemistry, whereas cytokeratin 19 (CK-19)
mRNA-positive circulating tumor cells (CTCs) in the peripheral
blood were identified by real-time PCR.
Results The incidence of CNS relapse was similar in patients
suffering from breast cancer or other solid tumors (10.4% and
11.4%, respectively; P = 0.517). The incidence of CNS relapse
was significantly higher in breast cancer patients with advanced
disease (P = 0.041), visceral disease and bone disease (P =
0.036), in those who were treated with a taxane-containing
regimen (P = 0.024), in those with HER2/neu-overexpressing
tumors (P = 0.022) and, finally, in those with detectable CK-19
mRNA-positive CTCs (P = 0.008). Multivariate analysis revealed
that the stage of disease (odds ratio, 0.23; 95% confidence
interval, 0.007–0.23; P = 0.0001), the HER2/neu status (odds
ratio, 29.4; 95% confidence interval, 7.51–101.21; P = 0.0001)
and the presence of CK-19 mRNA-positive CTCs (odds ratio,
8.31; 95% confidence interval, 3.97–12.84; P = 0.001) were
independent predictive factors for CNS relapse.
Conclusion CNS relapses are common among breast cancer
patients treated with a taxane-based chemotherapy regimen,
patients with HER2/neu-positive tumor and patients with CK-19
mRNA-positive CTCs.
Introduction
Breast cancer is the second leading cause of brain metas-
tases [1,2]. Based on autopsy reports, the incidence of central
nervous system (CNS) metastases among patients with
breast cancer is as high as 23% [3] but only 10–15% of these
patients will develop clinically overt (CNS) manifestations [2].
The problem of brain metastases will probably become more
important since patients survive longer [3,4], as a conse-
quence of more accurate diagnostic tools, of more aggressive
and effective adjuvant and locoregional treatment but, also, as
a consequence of better palliative therapy.
The factors influencing the development of brain metastases in
patients with breast cancer are poorly understood. Previous
studies have reported that negative hormonal receptor status
[5,6], HER2/neu overexpression [7,8] and the presence of
lung metastases [9,10] were associated with a higher risk for
the development of brain metastases. In addition, two other
studies reported a high incidence of CNS metastatic disease
CK-19 = cytokeratin 19; CNS = central nervous system; CTCs = circulating tumor cells; PCR = polymerase chain reaction; RT = reverse tran-
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in patients with locally advanced and metastatic breast cancer
treated with a taxane-containing chemotherapy regimen [9-
11].
The reasons for the association between treatment of breast
cancer with a taxane-containing chemotherapy regimen and
an increased incidence of CNS involvement are not clear.
Although taxanes are very lipophilic, their concentration in the
CNS is very low after their intravenous administration [12,13].
Moreover, preclinical data suggest that taxanes are unable to
penetrate the intact blood–brain barrier; in these models, the
concentration of radiolabeled paclitaxel in the cerebrospinal
fluid was found to be significantly lower than in other organs,
and thus was undetectable in the brain, in the spinal cord or in
any other site of the CNS [14].
It has more recently been proposed that paclitaxel is exported
from the p-glycoprotein and other ATP-binding cassette trans-
porters placed at the luminal membrane of brain capillaries, as
an explanation for the low concentrations of taxanes in the
CNS [15].
Furthermore, the detection of cytokeratin 19 (CK-19) and of
mRNA-positive circulating tumor cells (CTCs) in the peripheral
blood and the bone marrow of patients with breast cancer was
correlated with increased incidence of relapse in several stud-
ies [16,17]. The possible correlation of this finding with an
increased incidence of CNS relapse was not reported in any
of these studies.
During the past years we have frequently observed patients
with breast cancer treated with a taxane-containing chemo-
therapy regimen, either in the adjuvant setting or in the meta-
static setting, presenting CNS involvement as the only
evidence of disease progression. We were therefore inter-
ested to evaluate the incidence of CNS metastases in patients
with early and advanced breast cancer treated with a taxane-
containing chemotherapy regimen and to identify predictive
factors for CNS relapse.
Materials and methods
The medical files of all patients submitted to the Department
of Medical Oncology of the University General Hospital of Her-
aklion, Crete during the period January 2000–June 2003 were
retrospectively reviewed for the development of CNS meta-
static disease. Patients with a CNS relapse as the first and
only indication of metastatic disease or patients with isolated
CNS involvement diagnosed during or within three months of
the completion of previous chemotherapy were considered.
Four groups of patients with CNS metastatic disease were
identified: group A, patients with breast cancer treated with a
taxane-containing regimen; group B, patients with breast can-
cer treated with a nontaxane-containing regimen; group C,
patients with another type of solid tumor type treated with a
taxane-containing regimen; and group D, patients with another
type of solid tumor treated with a nontaxane-containing regi-
men. Groups B–D were used as controls.
For each patient with CNS metastatic disease, information
concerning tumor characteristics (histological type, grade,
HER2/neu status by immunohistochemistry with the CB-11
antibody, and estrogen receptor and progesterone receptor
status by immunohistochemistry), prior treatment (response to
treatment, time to tumor progression), type of CNS involve-
ment (cerebral metastasis, leptomeningeal carcinomatosis),
treatment of CNS metastasis and overall survival were
recorded. Leptomeningeal metastasis ought to have been
confirmed by CNS cytology. All medical files were reviewed by
two investigators (JS and LV). Computerized tomography of
the chest and abdomen and a bone scan were performed at
the time of CNS relapse as usual practice in our center. All
patients signed informed consent for the participation in clini-
cal trials and the use of the biologic material. The study was
approved by the Ethics and Scientific Committees of our Insti-
tution.
Peripheral blood mononuclear cells were prospectively
obtained from patients with either early breast cancer (stage I
and stage II) or advanced breast cancer (stage III and stage IV)
before the initiation of any chemotherapy, in order to identify
CTCs that express the CK-19 mRNA-positive cells. A quanti-
tative real-time RT-PCR assay was used for the detection of
CK-19 mRNA-positive CTCs, as previously described
[16,17]. We evaluated the presence of CK-19 mRNA-positive
CTCs in association with CNS relapse.
Statistical analysis was performed using the chi-square test for
the analysis of the two-dimensional contingency tables. The
two-sided significance level was set at P  < 0.05. A linear
regression analysis was performed to identify independent
predictive factors significantly influencing the incidence of
CNS involvement. Kaplan–Meier analysis was used in order to
estimate the probability of survival [18].
Results
Patient's characteristics
One thousand and forty-five previously untreated patients with
histologically or cytologically confirmed solid tumors were
enrolled in the present analysis of CNS involvement during the
predetermined 42-month study period. There were 305
patients in group A, 187 patients in group B, 416 patients in
group C and 137 patients in group D. Two hundred and fifty-
three patients and 239 patients presented early breast cancer
(stage I and stage II) and locally advanced/metastatic breast
cancer (stage III and stage IV), respectively. There was no dif-
ference in terms of median age, menopausal status and hor-
mone receptor or HER2/neu status in patients with early and
advanced breast cancer (Table 1). Taxane-containing chemo-
therapy regimens were administered either in the adjuvant set-Available online http://breast-cancer-research.com/content/8/4/R36
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ting or as frontline chemotherapy for metastatic disease in
50.2% and 74.5% of patients, respectively (Table 1).
CNS relapse in breast cancer patients
Fifty-one patients (10.4%) and 61 patients (11.4%) with
breast cancer or other solid tumors developed CNS meta-
static disease during the study period (P = 0.517).
The CNS involvement in breast cancer patients was cerebral
metastasis in 44 patients (86.3%), leptomeningeal involve-
ment in five patients (9.8%) and both cerebral metastasis and
leptomeningeal involvement in two patients (3.9%). Two lep-
tomeningeal metastases were recorded in patients with lobu-
lar tumor, and five in patients with ductal tumors.
In patients with other solid tumors, CNS involvement was cer-
ebral metastasis in 49 patients (80.3%), leptomeningeal dis-
Table 1
Breast cancer patient characteristics during the period January 2000–June 2003
Early stage breast cancer 
(n = 253)
Advanced/metastatic stage breast 
cancer (n = 239)
Central nervous system 
relapse (n = 51)
P value
Age (years) (median (range)) 51 (28–75) 53 (31–81) 55 (30–70)
Menopausal status
Premenopausal 109 (43.1) 108 (45.2) 31 (60.8) 0.071
Postmenopausal 144 (56.9) 131 (54.8) 20 (39.2)
Estrogen receptor status
Positive 118 (46.6) 126 (52.7) 25 (49) 0.51
Negative 120 (47.4) 105 (43.9) 25 (49)
Unknown 15 (6) 8 (3.3) 1 (2)
Histology
Ductal 195 (77) 182 (76.1) 38 (74.5) 0.287b
Lobular 20 (7.9) 21 (8.7) 5 (9.8)
Other 38 (15.1) 36 (16.2) 8 (15.6)
HER-2 status
Positive 31 (12.3) 43 (18) 27 (52.9) 0.002
Negative 130 (51.4) 124 (51.9) 16 (6.2)
Unknown 92 (36.4) 72 (30.1) 8 (4.8)
Dominant disease localization at baseline
Viscera - 134 (56) 27 (66)α 0.036c
Soft tissues - 63 (26.3) 6 (20)
Bones - 42 (17.5) 8 (14)
Cytokeratin 19 mRNA-positive cells
Positive 29 (12) 49 (21) 33 (65) 0.041
Negative 224 (88) 190 (79) 18 (35)
Taxane-based treatment
Yes 127 178 (75) 39 (12.8)
No 126 61 (25) 12 (6.4)
Response to chemotherapy -
Complete response + partial 
response
- 117 (49) 23 (56.3)a 0.59
Stable disease - 69 (29) 8 (18.7) 0.42
Progressive disease - 53 (22) 10 (25) 0.55
Data presented as n (%). aProportion of patients corresponds to the 41 patients with advanced/metastatic disease. bP value corresponds to the 
incidence of central nervous system relapses between patients with lobular and ductal histology. cP value corresponds to the incidence of central 
nervous system relapses between patients with visceral disease localization and other disease sites (soft tissue + bones).Breast Cancer Research    Vol 8 No 4    Souglakos et al.
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ease in nine patients (14.8%) and both cerebral metastasis
and leptomeningeal disease in three patients (4.9%).
The median progression-free interval for the whole group of
patients with breast cancer who developed CNS relapse was
5 months (range, 1–9 months), and that for patients with other
solid tumors was 5.5 months (range, 1–7.5 months). The
median progression-free intervals were 7 months (range, 4–9
months) and 4.5 months (range, 1–6 months) in patients with
early breast cancer and advanced/metastatic breast cancer,
respectively.
Forty-two of the 51 relapsed patients (82.4%) were treated
with whole brain radiotherapy, four patients (7.8%) with whole
brain and spinal cord radiotherapy, and one patient with
intrathecal chemotherapy and radiotherapy, while four patients
(4.7%) did not receive further treatment. The median survival
time for the whole group of CNS relapsed breast cancer
patients was 8.5 months (range, 1–25 months) and the 1-year
survival rate was 12.3%. The median survival times were 10
months (range, 2–25 months) and 8 months (range, 1–19
months) for patients with early breast cancer and advanced/
metastatic breast cancer, respectively.
CNS involvement according to the biological and clinical 
characteristics of breast cancer
Table 1 indicates that the incidence of CNS involvement was
higher in premenopausal patients than in postmenopausal
patients (60.8% versus 39.2%, respectively; P = 0.071). In
addition, CNS relapses were equally distributed in patients
with estrogen receptor-positive and estrogen receptor-nega-
tive tumors (P = 0.51). Conversely, a significantly higher inci-
dence of CNS relapses was observed in patients with
advanced/metastatic disease compared with early stage dis-
ease (41 patients (17.1%) and 10 patients (3.9%), respec-
tively; P = 0.041), in patients with visceral (n = 27 patients,
52.9%) disease compared with only soft tissue metastases (n
= 6, 11.8%; P = 0.036), in patients with HER2/neu-overex-
pressing tumors compared with HER2/neu-negative tumors
(52.9% and 31.4%, respectively; P = 0.002), in patients with
detectable occult CK-19 mRNA-positive CTCs in the periph-
eral blood compared with those without CK-19 mRNA-posi-
tive cells (64.7% and 35.3%, respectively; P = 0.041), and in
patients who received a taxane-containing chemotherapy reg-
imen (group A) compared with those who were treated with a
nontaxane-containing chemotherapy regimen (group B)
(76.5% and 23.5%, respectively; P = 0.024).
In addition, 43 patients with metastatic disease and HER-2
overexpression in the primary tumor were treated with Trastu-
zumab. Sixteen (37.2%) of those patients presented CNS
relapse during their treatment. Table 2 indicates that in
patients with other solid tumors the used chemotherapy regi-
men did not influence the incidence of CNS involvement
(group C, 7.6%; group D, 6.5%; P = 0.196).
CNS relapse as the unique manifestation of disease 
progression
In 40 out of 51 patients (78.4%) the CNS relapse was the
unique manifestation of disease progression. Thirty-two (80%)
and eight (20%) of these relapses occurred in group A
patients and group B patients, respectively (P = 0.067). Table
3 indicates that the incidence of CNS involvement as the
unique site of disease progression was higher in stage III/
stage IV group A patients (65%) than in group B patients
(12.5%; P = 0.082) as well as in stage I/stage II patients (15%
and 7.5%, respectively; P = 0.114). In addition, among the 40
patients with early breast cancer and advanced/metastatic
breast cancer who presented an isolated CNS relapse, 23
patients (57.5%) had HER2/neu-positive (grade 2+ and grade
3+) tumors and 11 patients (27.5%) had HER2/neu-negative
(grade 0+ and grade 1+) tumors (P = 0.002). Similarly, 26 of
these 40 patients (65%) displayed detectable CK-19 mRNA-
Table 2
Incidence of central nervous system (CNS) relapses in patients with breast cancer and types other of solid tumor according to the 
administered chemotherapy regimen
Patients CNS relapses P value
n Percentage
Group A (n = 305) 39 12.8 0.024a
Group B (n = 187) 12 6.5
Group C (n = 416) 32 7.6 0.196b
Group D (n = 137) 9 6.5
Group A, patients with breast cancer treated with a taxane-containing regimen; group B, patients with breast cancer treated with a nontaxane-
containing regimen; group C, patients with another type of solid tumor type treated with a taxane-containing regimen; and group D, patients with 
another type of solid tumor treated with a nontaxane-containing regimen. aP value corresponds to the incidence of CNS relapses between groups 
A and B. bP value corresponds to the incidence of CNS relapses between groups C and D.Available online http://breast-cancer-research.com/content/8/4/R36
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positive CTCs in the peripheral blood and 14 patients (35%)
did not (P = 0.004).
Multivariate analysis
Table 5 demonstrates that the stage of disease (odds ratio,
0.23; P < 0.0001), the detection of CK-19 mRNA-positive
CTCs (odds ratio, 8.31; P = 0.001) and the HER2/neu status
(odds ratio, 29.41; P < 0.0001) emerged as independent pre-
dictive factors for CNS relapse. A trend towards a significant
difference was also observed for the response to treatment (P
= 0.096; Table 5). Similarly, the multivariate analysis of the dif-
ferent parameters performed in the 40 patients in whom CNS
relapse was the only manifestation of disease progression
revealed the same predictive factors for CNS relapse (stage of
the disease: odds ratio, 0.28 P < 0.001; detection of CK-19
mRNA-positive CTCs: odds ratio, 8.97; P < 0.001; HER2/neu
status: odds ratio, 30.42; P < 0.0001). A trend towards a sig-
nificant difference for the response to treatment was again
detected (P = 0.097).
Discussion
The development of brain metastases is usually a late event in
the natural history of uncontrolled cancer. Despite increased
interest during past years there are very few established pre-
dictive factors associated with the occurrence of CNS meta-
static disease in patients with breast cancer. It is a common
clinical experience that brain metastases occur more fre-
quently in young women with large and/or aggressive tumors
[4]. Several studies have also demonstrated that the negative
hormonal receptor status and the presence of lung metas-
tases may be associated with a higher risk of developing brain
metastases [5,6,8,10]. In addition, recent studies reported
that breast cancer patients who received a taxane-containing
chemotherapy regimen had a significantly higher incidence of
CNS metastases compared with that of patients treated with
a nontaxane-containing regimen [9,11]. There are also data
indicating an increased risk for brain metastases in breast can-
cer patients receiving trastuzumab [8,19-22].
The results of the present study demonstrate that the overall
incidence of CNS metastatic disease in patients with breast
cancer (both early breast cancer and advanced/metastatic
breast cancer) is not different from that observed in patients
with other types of solid tumors. The multivariate analysis,
however, demonstrated that the stage of the disease, the
HER2/neu status (grade 2+ or grade 3+ by immunohisto-
chemistry) and the presence of CK-19 mRNA-positive CTCs
represent independent predictive factors for CNS relapse.
The same parameters emerged as independent predictive fac-
tors in the subgroup of breast cancer patients in whom the
CNS involvement was the unique site of disease progression.
The predictive value of the HER2/neu status already reported
[8,9] was further confirmed in the present study. Moreover, it
has been shown that the HER2/neu status of the brain metas-
tases is similar and highly concordant (97%) with that of the
primary tumor, suggesting that the HER2/neu status of the pri-
mary tumor is predictive of the HER2/neu status of the tumors.
Table 3
Incidence of central nervous system metastasis as the only manifestation of disease progression according to the stage of disease
CNS relapses (n = 40) P value
Group A (n = 32) Group B (n = 8)
Stage I/stage II 6 (15%) 3 (7.5%) 0.367
Stage IIIb/stage IV 26 (65%) 5 (12.5%) 0.143
All stages 32 (80%) 8 (20%) 0.048
Group A, patients with breast cancer treated with a taxane-containing regimen; group B, patients with breast cancer treated with a nontaxane-
containing regimen.
Table 4
Incidence of central nervous system relapses as the only manifestation of disease progression in breast cancer patients according 
to the detection of cytokeratin 19 mRNA-positive cells in peripheral blood
Cytokeratin 19 mRNA cells CNS relapses (n = 40) P value
n Percentage
Positive (n = 78) 26 33.3 0.004
Negative (n = 414) 14 3.4Breast Cancer Research    Vol 8 No 4    Souglakos et al.
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The time to develop CNS metastatic disease seems to be
shorter in patients with HER2/neu-positive brain lesions, dem-
onstrating the importance of evaluating the HER2/neu status
early in the diagnosis of breast cancer in order to provide infor-
mation on the patient's prognosis and to assist clinical deci-
sion-making. It has been reported that 25% of metastatic
breast cancer patients developed CNS metastatic disease
during treatment with trastuzumab [20], and that nearly 10%
of patients receiving trastuzumab in combination with chemo-
therapy developed isolated CNS metastases as the first site of
tumor progression [22]. In addition, almost 15% of patients
with disseminated breast cancer had occult CNS metastases
and the only predictive factors for this evolution were the
number of sites involved and the HER2/neu status [8].
A possible explanation for these observations could be a pre-
dilection of HER2/neu tumors to developed CNS metastases.
Alternatively, we cannot exclude that trastuzumab may control
the systemic disease, leading to an improved survival [23].
Since trastuzumab cannot cross the blood–brain barrier, how-
ever, the CNS remains a vulnerable 'sanctuary site'. Irrespec-
tive of the reasons for the observed increased incidence of
brain metastases in patients with HER2/neu-overexpressing
breast cancer, the practical problem remains the development
of CNS disease, which has an extremely poor prognosis. It is
therefore important to develop a risk assessment and thera-
peutic strategy in order to prevent and/or control CNS dis-
ease, aiming at prolonging patient survival.
We also observed that the incidence of brain metastases was
significantly higher in patients with visceral disease than soft
tissue disease, despite the fact that this parameter did not
emerge as an independent predictive factor in the multivariate
analysis. Although we did not discriminate between pulmonary
and other visceral localizations of disease, this finding is in
agreement with other studies [8-10] reporting a higher inci-
dence of brain metastases in patients with lung metastases
(nearly 30%). This higher incidence of brain metastases in
patients with visceral disease is common evidence in retro-
spective studies [9,20] and should probably be attributed to
the more aggressive biologic behavior of these tumors and the
higher probability of hematogeneous dissemination of malig-
nant cells in these patients. We have also reported that
patients with CK-19 mRNA-positive CTCs have increased
incidence for relapse with metastatic disease [17,24]. Moreo-
ver, our observation that the detection of CK-19 mRNA-posi-
tive CTCs was associated with an increased risk of CNS
involvement in patients with breast cancer further support the
hypothesis.
This finding was not surprising since the detection of CK-19
mRNA-positive tumor cells in the peripheral blood [17,24] or
in the bone marrow [25,26] represents an independent pre-
dictive and prognostic factor for early clinical relapse and
death from the disease. Indeed, the circulating CK-19 mRNA-
positive tumor cells have the possibility, through the blood vas-
culature, to reach every tissue. The development of clinically
overt metastatic disease is not a random phenomenon accord-
ing to the 'seed and soil' theory, since the homing ability of
these circulating tumor cells is determined by their biological
characteristics as well as by other biological factors of the
local environment [27]. Maguire and colleagues have reported
the detection of cytokeratin-positive cells in bone marrow aspi-
rates in 12 out of 12 cancer patients with CNS relapse; in nine
of these patients, bone marrow occult cells were the only evi-
dence for systemic spread [28]. The validation of the predic-
tive value of CK-19 mRNA-positive cells for CNS relapse,
however, requires a prospective study with a higher number of
patients, a more prolonged follow-up period and further molec-
ular and biological characterization of peripheral blood CK-19
mRNA-positive occult tumor cells.
In the present study it was also possible to confirm the initial
clinical observation that breast cancer patients who receive a
taxane-containing chemotherapy regimen have a significantly
higher incidence of CNS metastases compared with that of
Table 5
Multivariate analysis of risk factors for central nervous system metastasis for the whole study population
Variable Odds ratio 95% confidence interval P value
Stage of disease 0.23 0.007–0.34 0.0001
Taxane-based regimen 1.61 0.71–3.63 0.246
Line of therapy 1.64 0.67–2.76 0.208
Cytokeratin 19 mRNA-positive 
circulating tumor cells
8.31 3.97–12.84 0.001
Premenopausal 1.9 0.58–6.45 0.278
Response to treatment 0.81 0.57–4.65 0.096
HER-2 status 29.41 7.51–101.21 0.0001
Visceral disease 1.8 0.84–3.17 0.211
Dependent variable, central nervous system relapses.Available online http://breast-cancer-research.com/content/8/4/R36
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patients treated with a nontaxane-containing regimen. Never-
theless, this parameter did not emerge as an independent pre-
dictive factor in the multivariate analysis. It is important to note,
however, that a similar difference was not observed in patients
with other types of solid tumor treated or not with a taxane-
containing chemotherapy regimen.
Taxanes are highly effective in breast cancer and they prolong
the survival of patients with advanced disease. It is also well
known that CNS involvement is more frequent in the late
stages of the disease. A possible explanation could therefore
be that the increase in survival and the prolonged period of
advanced disease is correlated with the increased frequency
of CNS relapse. It is important to note that such a correlation
could represent a confounding factor, in a retrospective anal-
ysis. For example, someone can hypothesize that physicians
may have chosen more aggressive treatment for patients with
aggressive tumors. These patients also showed increased
incidence for CNS relapse. Although this observation could be
explained with the 'sanctuary site' hypothesis, experimental
studies in mice have demonstrated that the blood–brain bar-
rier is intact inside and around brain metastases smaller than
0.2 mm2 but not in larger lesions [29]. This finding implies that
the barrier should not be a major obstacle to using chemother-
apy in the treatment of brain metastases, at least in the
advanced stages of the disease. In addition, more recent stud-
ies have shown that paclitaxel is exported by the p-glycopro-
tein and other ATP-binding cassette transporters placed at the
luminal membrane of brain capillaries [15].
The aforementioned data suggest that taxanes may not pene-
trate well into the CNS, and therefore the CNS may represent
tumor 'sanctuary' sites for taxane-containing chemotherapy
regimens. A difference in the incidence of CNS relapses
between patients with breast cancer and other solid tumors
treated with taxanes was observed. This difference in the inci-
dence of CNS relapse between patients with breast cancer
and other solid tumors could be explained by the higher effi-
cacy of the taxanes in breast cancer which is associated with
increased survival in comparison with other solid tumors.
We have previously reported that the use of Transtuzumab
could decrease or eradicate CK-19 mRNA-positive CTCs
[30]. Based on these results we have initiated a randomized
clinical trial to evaluate the effect of Transtuzumab administra-
tion on the disease-free survival of patients with early breast
cancer and CK-19 and HER-2 mRNA-positive CTCs. The inci-
dence of CNS relapse in correlation with the detection of CK-
19 mRNA-positive CTCs will be prospectively evaluated in this
ongoing study.
Conclusion
Our study raises some interesting approaches that could be of
relevance in the daily clinical practice: evaluating the incorpo-
ration of prophylactic CNS irradiation in patients with breast
cancer who present unfavorable predictive factors for CNS
relapse (that is, HER2/neu tumors, visceral metastases with
detectable CK-19 mRNA-positive CTCs); the evaluation and
development of new therapeutic approaches and strategies to
treat occult tumor cells before the development of overt clini-
cal relapse; and, since in the future we are going to treat more
patients with isolated brain metastases, the need to develop
new and more aggressive diagnostic, therapeutic and follow-
up approaches. Further studies are therefore warranted to bet-
ter understand and investigate the characteristics of this par-
ticular clinical evolution of patients with breast cancer and,
thus, to more effectively treat these patients.
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